本轮融资由高特佳领投，资金将加速推进公司产品的创新研发和商业化进程，为神经介入专家提供更优 的治疗方式。 近日，苏州无限医疗科技有限公司（Infinity Neuro）——一家专注为神经血管外科提供创新解决方案的 医疗器械公司宣布，已完成数亿元人民币的A轮融资。 无限医疗（Infinity Neuro）主要从事脑血管领域医疗器械的研发、生产和商业化，致力于与神经科医生 深入合作，聚焦神经介入领域未被满足的临床需求，产品覆盖治疗出血性和缺血性卒中的两大核心产品 线。核心团队均来自于跨国医疗器械公司，拥有多次成功创业经历，核心团队深度聚焦神经介入领域出 血性和缺血性卒中市场，具有神经介入医疗器械产品研发、临床、产业化及产品迭代升级的丰富经验。 ...

本轮资金将主要用于加速其全原子模型蛋白质设计平台Pallatom的技术迭代、商业化产品管线的拓展以 及全球化人才的引进。需要特别指出的是，Pallatom在全球首次解决了混旋性环肽设计难题，为新一代 环肽药物的管线开发开辟了新路径。 12月9日，AI蛋白质设计领域的领先企业杭州力文所生物科技有限公司（Levinthal Biotech，以下简 称"力文所"）宣布成功完成数千万人民币Pre-A轮融资。本轮融资由金雨茂物领投，君科丹木跟投，舟 渡资本担任独家财务顾问。 ...

近日，远大医药集团发布公告称，公司用于治疗抑郁症的中药创新药GPN01360在中国开展的II期临床 研究成功达到临床终点。 该研究是一项随机、双盲、安慰剂平行对照、多中心的II期临床研究，入组148例抑郁症患者，口服给 药8周，旨在初步评价该药相较于安慰剂治疗抑郁症（肝郁脾虚证）的有效性和安全性。结果表明，该 药在抑郁症的治疗方面有较好的安全性和有效性，且对抑郁伴焦虑、失眠等症状的改善也较为明显。 ...

Core Viewpoint - The introduction of Novo Nordisk's long-acting growth hormone, Pasi Growth Hormone Injection, at Boao Future Hospital provides a new treatment option for children with Growth Hormone Deficiency (GHD) in China, showing promising results in height increase within three months [1] Group 1: Product Introduction - Pasi Growth Hormone Injection has been introduced as a clinically needed drug and has already benefited over 20 children aged between 4.5 to 14.5 years with GHD [1] - The drug has demonstrated a height increase of 3-4 cm within three months of treatment [1] Group 2: Technology and Mechanism - The drug utilizes a mature technology known as fatty acid derivatization, which has been in use internationally for 36 years [1] - This technology involves single amino acid substitution in the GH molecule and reversible binding with endogenous albumin via fatty acid side chains, enhancing drug bioactivity and distribution [1] - The method allows for a prolonged half-life and sustained action, enabling administration only once a week [1] Group 3: Safety and Efficacy - The safety profile of Pasi Growth Hormone is supported by 7 years of clinical trials and real-world observations, indicating good safety characteristics [1] - The molecular structure of Pasi Growth Hormone is similar to that of human growth hormone, with metabolism primarily relying on the body's own albumin [1]

#贝壳董事长彭永东售股兑现捐赠承诺#【#贝壳董事长彭永东首次售股为公益# 投入服务者和家属医 疗、毕业生安居】12月9日，美股文件显示，贝壳董事长彭永东首次出售股票，兑现捐赠承诺。4月，贝 壳公告彭永东拟捐赠900万股A类普通股，彼时外界评估价值约4.4亿元。捐赠50%税后资金将用于居住 行业服务者及其家庭成员的医疗健康福利，50%税后资金将用于应届毕业生等群体的租房帮扶。 Q3财报披露后，包括高盛、摩根士丹利等多家大行集体维持对贝壳"买入"或"增持"评级。（智通财经） ...

Core Viewpoint - The company emphasizes that despite a positive short-term consumption trend during the holiday season, the overall consumption level is unlikely to return to previous highs, indicating a new normal in the market [1][3]. Group 1: Consumption Trends - The company observed a good consumption trend in October due to a longer holiday, increased willingness for compliant gatherings, and a rise in gifting local liquor [1]. - However, as life returns to normal in November, the consumption heat is expected to decline, suggesting a more subdued market environment [1]. - Online sales during the Double Eleven event showed positive growth compared to last year, aligning with the company's expectations and enhancing brand penetration in online consumption [1]. Group 2: Pricing and Inventory Management - The company acknowledges that e-commerce platform subsidies have a short-term impact on pricing but believes the long-term effects are limited due to low online penetration of liquor sales and consumer awareness of subsidies [2]. - The management stated that they will not intentionally pursue additional channel payments to maintain price stability, as this could lead to significant price disparities and weaken brand differentiation [2][3]. - The company is focused on maintaining a healthy inventory level and optimizing market conditions rather than pursuing superficial sales boosts [3]. Group 3: Future Growth Strategies - The company plans to continue expanding its product range across various price segments, with a focus on core products and new market opportunities [3]. - There is a recognition of the need for low-alcohol products to attract new consumer demographics, with the industry beginning to explore this segment more seriously due to current market pressures [4][5]. - The company believes that while younger consumers may initially avoid traditional liquor, they will likely engage with it as they age, particularly favoring lower-alcohol, higher-quality options [5].

Core Insights - Maserati is facing significant challenges in the Chinese market, with a continuous decline in sales and a reduction in the number of dealerships [1][7][8] - The brand has implemented substantial price reductions on its models, particularly the Grecale, in an attempt to clear inventory and stimulate sales [3][4][7] - Frequent management changes within Maserati have contributed to instability and may be impacting the brand's performance in China [9] Dealership and Sales Performance - Maserati has closed two of its three 4S dealerships in Beijing, leaving only the Poly Maserati dealership operational [1][7] - The remaining dealership is offering significant discounts, with the Grecale fuel version priced at 388,800 yuan after a 40% reduction from its original price [3][7] - Maserati's sales in China have been declining since 2018, with projected sales of 4,680 units in 2022, 4,367 units in 2023, and a drastic drop to 1,209 units in 2024 [7] Pricing Strategy - The Grecale electric SUV is being offered at a starting price of 358,800 yuan, down from an official price of 898,800 yuan, representing a discount of 540,000 yuan [4][7] - The fuel version of the Grecale has also seen a price drop, with discounts exceeding 260,000 yuan from its original price range of 650,800 to 1,038,800 yuan [4][7] Management Changes - Maserati has experienced frequent leadership changes, with three different general managers in less than two years, indicating potential instability in strategic direction [9] - The latest management appointments include Fabio Lambertini in May 2023 and a subsequent change to Julie Taieb-Doutriaux in March 2024 [9] Market Adaptation Efforts - Maserati is attempting to address market challenges through a dual strategy of electric and fuel models, with new electric versions of existing models [12] - The brand is focusing on enhancing customer experience and engagement through personalized services and cultural integration initiatives [12] - Efforts to adapt to local market demands include streamlining decision-making processes and fostering community engagement among owners [12]

12月8日，国家金融监督管理总局河北监管局发布批复，核准刘阳冀银金融租赁股份有限公司副总裁的任职资格。 批复显示，冀银金融租赁应要求上述核准任职资格人员严格遵守金融监管总局有关监管规定，自本行政许可决定作出之日起3个月内到任，并按要求及时报 告到任情况。未在上述规定期限内到任的，本批复文件失效，由决定机关办理行政许可注销手续。 （国家金融监督管理总局） 同时，冀银金融租赁应督促上述核准任职资格人员持续学习和掌握经济金融相关法律法规，牢固树立风险合规意识，熟悉任职岗位职责，忠实勤勉履职。 ...

Core Viewpoint - Yunji's CEO Zhang Junbin denied rumors of a potential acquisition by Joyoung, emphasizing that the company is focused on its upcoming IPO in Hong Kong [1] Group 1: Company Developments - The CEO stated that online rumors are intended to undermine the company's morale, and any significant developments would be communicated promptly [1] - In April, Yunji completed a financing round of 100 million USD, with the company's valuation exceeding 10 billion USD [1] - The employee stock option pool is larger than the CEO's personal shareholding, indicating strong employee incentives and confidence in the company's future [1]

Core Viewpoint - Fujian Makeng Mining Co., Ltd. has received approval for its IPO on the Shanghai Stock Exchange, aiming to raise 1 billion yuan for expansion projects in iron ore mining [1][2] Group 1: Company Overview - Fujian Makeng Mining Co., Ltd. is located in Longyan City, Fujian Province, a historically significant revolutionary area, and is engaged in the development and comprehensive utilization of iron ore resources [1] - The company primarily focuses on the mining and sales of iron ore, iron concentrate, molybdenum concentrate, and limestone [1] - The company holds mining rights for the well-known Makeng Iron Mine, with iron ore reserves of 330.39 million tons and associated molybdenum reserves of 44,300 tons (measured in metal content) [1] Group 2: Financial Performance - The company's revenue from 2022 to the first half of 2025 is reported as follows: 2.057 billion yuan in 2022, 1.962 billion yuan in 2023, 2.05 billion yuan in 2024, and 1.045 billion yuan in the first half of 2025 [1] - Corresponding net profits attributable to the parent company for the same period are 659 million yuan, 651 million yuan, 664 million yuan, and 362 million yuan respectively [1] Group 3: IPO and Expansion Plans - The IPO aims to raise 1 billion yuan, which will be invested in the Makeng Iron Mine expansion project [2] - The expansion project is expected to add 5 million tons per year of iron ore mining capacity, significantly increasing the company's production scale [2] - This project will enhance the efficiency of existing production facilities, reduce unit production costs of iron concentrate, and improve the company's profitability and sustainability [2]